Study to evaluate potential COVID-19 treatment regimen in hospitalized patients
The National Institute of Allergy and Infectious Diseases has launched a clinical trial to evaluate a potential COVID-19 treatment regimen for hospitalized patients that combines remdesivir with interferon beta-1a, a medication approved to treat multiple sclerosis that laboratory studies suggest may benefit patients with COVID-19.
The trial expects to enroll more than 1,000 hospitalized adults with COVID-19 in the United States and abroad who have abnormal chest X-rays or need supplemental oxygen or mechanical ventilation. Preliminary results are expected this fall.
Related News Articles
Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…